Congenital Adrenal Hyperplasia Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: April 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 27.03 million |
|
Revenue Forecast in 2031 |
US$ 50.97 million |
|
CAGR |
7.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Treatment, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global congenital adrenal hyperplasia treatment market was valued at US$ 27.03 million and is expected to register a revenue CAGR of 7.3% to reach US$ 50.97 million in 2031.
Congenital Adrenal Hyperplasia Treatment Market Fundamentals
Congenital adrenal hyperplasia (CAH) is a group of inherited disorders that affect the adrenal glands, which produce hormones that regulate various bodily functions. The treatment of congenital adrenal hyperplasia depends on the condition's specific type and severity. Currently, there are no breakthroughs in the treatment of congenital adrenal hyperplasia. Hormone replacement therapy to replace the deficient hormones, such as cortisol and aldosterone, and to suppress the overproduction of androgens is considered the standard congenital adrenal hyperplasia treatment. Some types of congenital adrenal hyperplasia may require lifelong hormone replacement therapy, while others may only require monitoring and occasional congenital adrenal hyperplasia medication adjustments. Individuals with this disease must work closely with their healthcare provider to develop a personalized treatment plan. However, ongoing research is focused on improving congenital adrenal hyperplasia management through the development of new medications, gene therapies, and improved surgical techniques. For example, researchers are exploring gene editing technologies to correct genetic mutations. Other researchers are developing new medications that can more precisely target the underlying hormonal imbalances in this disease. For instance, one recent study published in the New England Journal of Medicine in 2021 reported successful gene therapy for a rare form of congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency. The researchers used a modified adeno-associated virus (AAV) vector to deliver a functional copy of the CYP21A2 gene, which produces the enzyme deficient in CAH patients. The gene therapy was well-tolerated and led to sustained normalization of cortisol levels in the treated patients.
[8686]
Congenital Adrenal Hyperplasia Treatment Market Dynamics
Congenital adrenal hyperplasia in infants affects 1 in 16,000 to 1 in 20,000 people worldwide. Although the incidence may appear to be increasing, this is more likely the result of better diagnostic tools and higher awareness than the actual rise in the number of cases. The revenue growth of the congenital adrenal hyperplasia treatment market is the rising prevalence of congenital adrenal hyperplasia. As medical knowledge and technology advance, more cases of congenital adrenal hyperplasia are being identified and diagnosed, which generates lucrative opportunities for the global congenital adrenal hyperplasia treatment market revenue. Newborn screening for congenital adrenal hyperplasia is routine in many countries, leading to earlier detection and treatment. Early detection and treatment of congenital adrenal hyperplasia can prevent life-threatening complications and improve the quality of life for affected individuals.
Many countries now screen newborns for CAH in routine newborn screening programs. The screening typically involves measuring levels of 17-hydroxyprogesterone (17-OHP) in a blood sample. Elevated levels of 17-OHP may indicate CAH and prompt further diagnostic testing. Also, hormone testing and genetic testing are now used to measure levels of various hormones affected by CAH, including cortisol, aldosterone, and androgens.
Furthermore, robust pipeline drugs support the global congenital adrenal hyperplasia treatment market trends. The pipeline drugs are expected to offer better efficacy and safety profiles than the existing treatments, likely to drive the market revenue growth. Increasing awareness about congenital adrenal hyperplasia and its treatment options is also expected to contribute to market revenue expansion. Some pipeline drugs currently being developed for CAH include adreno corticotropic hormone analogs, synthetic versions of the hormone ACTH, often used to stimulate cortisol production in patients with CAH. Also, steroidogenic enzyme inhibitors are designed to inhibit specific enzymes producing cortisol and other hormones. By targeting these enzymes, these drugs may reduce the overproduction of androgens and other hormones that can lead to congenital adrenal hyperplasia symptoms.
Advances in genetics research have led to a better understanding of disease and its treatment. This has led to the development of personalized approaches to medicine. In addition, healthcare costs continue to rise, and personalized medicine can potentially reduce healthcare costs by providing more targeted and effective treatments. Therefore, increasing personalized treatment demand and increased focus on developing effective treatments for rare diseases are improving the global congenital adrenal hyperplasia treatment market revenue. Government initiatives have also focused on improving access to treatments for rare diseases such as congenital adrenal hyperplasia.
In some cases, this may involve funding for the development of new treatments or for the purchase of existing treatments for patients who cannot afford them by encouraging patient advocacy groups, which provide support and resources for patients and families affected by rare diseases. These groups can help to raise awareness of rare diseases and advocate for better treatment and access to care. Some governments also provide regulatory incentives for developing and approving treatments for rare diseases.
However, due to a lack of proper knowledge, most of the time, the disease remains undetected. A major global congenital adrenal hyperplasia market challenge is the lack of proper diagnosis in many low- and middle-income countries. The inflated cost of congenital adrenal hyperplasia treatment also hinders market revenue growth.
Congenital Adrenal Hyperplasia Treatment Market Ecosystem
The global congenital adrenal hyperplasia treatment market overview is analyzed from four perspectives: type, treatment, distribution channel, and region.
Congenital Adrenal Hyperplasia Treatment Market by Type
[856856]
Based on the type, the global congenital adrenal hyperplasia treatment market is segmented into classic congenital hyperplasia and non-classic congenital hyperplasia.
Classic congenital hyperplasia accounted for the largest revenue share of the global congenital adrenal hyperplasia treatment market in 2022. Classic congenital adrenal hyperplasia is the most common type of congenital adrenal hyperplasia and accounts for around 95% of total congenital adrenal hyperplasia cases. As a result, a larger patient population needs treatment for classic CAH compared to the non-classic type. As a result, the market for CAH treatment is dominated by treatments for classic CAH. The standard treatment for classic congenital adrenal hyperplasia involves hormone replacement therapy, which replaces the deficient hormones and helps to restore normal hormone levels. This therapy typically involves using glucocorticoids to replace cortisol and mineralocorticoids to replace aldosterone. The standard treatment protocols for classic congenital adrenal hyperplasia are well-established and have been used for many years. This has led to the development of a range of medications and therapies specifically designed to treat classic congenital adrenal hyperplasia. There has been a strong focus on research into classic congenital adrenal hyperplasia, which has led to a better understanding of the underlying biology of the condition and the development of new treatments. This has further reinforced the dominance of classic congenital adrenal hyperplasia in the congenital adrenal hyperplasia treatment market.
Congenital Adrenal Hyperplasia Treatment Market by Treatment
Based on the treatment, the global congenital adrenal hyperplasia treatment market is segmented into hormone replacement therapy, steroids, salt supplements, and others.
The hormone replacement therapy segment accounted for the largest revenue share of the global congenital adrenal hyperplasia treatment market in 2022. According to the global congenital adrenal hyperplasia treatment market, the hormone replacement therapy segment is the most effective treatment for CAH. The first-line drug for congenital adrenal hyperplasia (CAH) treatment depends on the type and severity of the condition. For classic CAH, the most common type of CAH, the first-line treatment typically involves oral hydrocortisone, a synthetic glucocorticoid that mimics the actions of cortisol. The goal of treatment is to provide enough glucocorticoids to suppress the overproduction of androgens while also avoiding the side effects of excess glucocorticoid exposure.
In some cases, other medications may be combined with hormone replacement therapy to treat congenital adrenal hyperplasia. For example, mineralocorticoids such as fludrocortisone may be used to replace the aldosterone hormone, which is also deficient in some types of CAH. Other medications, such as anti-androgens, GnRH agonists, or aromatase inhibitors, may be used in certain cases to help manage symptoms and reduce androgen levels.
Congenital Adrenal Hyperplasia Treatment Market by Distribution Channel
Based on the distribution channel, the global congenital adrenal hyperplasia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies accounted for the largest revenue share of the global congenital adrenal hyperplasia treatment market in 2022. The medication prescribed by medical professionals for congenital adrenal hyperplasia treatment must be dispensed by hospital pharmacies that cover glucocorticoids and additional drugs frequently used to treat the illness. The standard gold treatment for congenital adrenal hyperplasia is hormone replacement therapy, for which hospitals are the most preferred places. Along with hospitals, the attached pharmacy plays a crucial role in monitoring the use of medications in patients with CAH. This includes tracking medication adherence, identifying potential medication interactions or adverse effects, and adjusting medication doses.
Congenital Adrenal Hyperplasia Treatment Market by Region
Based on the region, the global congenital adrenal hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global Congenital Adrenal Hyperplasia Treatment market in 2022. With respect to the congenital adrenal hyperplasia treatment market during the forecast period, it is expected that well-established hospitals and healthcare infrastructure will be able to manage the increase in demand for congenital adrenal hyperplasia treatment in North America. Moreover, advanced research and development countries in North America are considered hubs for safe and effective treatments, such as gene therapy for CAH. Additionally, the market in this area is expected to develop due to the rising prevalence of congenital adrenal hyperplasia and increased public awareness of the potential treatment choices. Furthermore, the region's need for congenital adrenal hyperplasia treatment is expected to increase due to favorable reimbursement policies and government measures to upgrade healthcare facilities.
Congenital Adrenal Hyperplasia Treatment Market Competitive Landscape
Multiple companies across the globe are investing in raising awareness and reimbursement, which is expected to improve the congenital adrenal hyperplasia treatment market outlook. Notable market participants operating in the global congenital adrenal hyperplasia treatment market accounting for the largest revenue share include,
Congenital Adrenal Hyperplasia Treatment Market Strategic Developments
Congenital adrenal hyperplasia (CAH) is a group of genetic disorders that affect the adrenal gland's ability to produce hormones such as cortisol and aldosterone.
Classic congenital hyperplasia accounted for the largest revenue share of the global congenital adrenal hyperplasia treatment market.
Asia Pacific region is expected to be the fastest-growing market revenue share for congenital adrenal hyperplasia treatment.
Key companies operating the global Congenital Adrenal Hyperplasia Treatment market are Emerge Health, Sentia Medical Sciences, Inc., Millendo, Therapeutics, Inc., Spruce Biosciences, Inc., Adrenas Therapeutics, Inc., and Alder Biopharmaceuticals, Inc.
The global congenital adrenal hyperplasia treatment market is expected to register a revenue CAGR of 7.3% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain